BOSTON, Massachusetts — March 4, 2026 — Leads & Copy — Bicara Therapeutics Inc. (Nasdaq: BCAX) announced it awarded an inducement grant on March 2, 2026, to a new employee as a material inducement to employment.
The clinical-stage biopharmaceutical company, which focuses on bifunctional therapies for solid tumors, granted a non-qualified stock option to purchase 115,000 shares of its common stock. The par value is $0.0001 per share, with an exercise price of $17.59 per share, matching the closing price of Bicara’s common stock on Nasdaq on March 2, 2026.
The shares vest, with one-fourth on the first anniversary of the employee’s start date. The remaining shares vest in 12 equal quarterly installments, contingent on the employee’s continued service with the company.
The award was granted outside of Bicara’s stockholder-approved equity incentive plans, under Bicara’s 2026 Inducement Plan, adopted by the board of directors in January 2026. The compensation committee of the board, comprised of independent directors, approved the award as a material inducement for the employee’s employment, following Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics is focused on transformative bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to improve tumor penetration by addressing challenges in the tumor microenvironment that have previously hindered the treatment of various solid tumor cancers.
Ficerafusp alfa combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). This targeted mechanism aims to reverse the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling, facilitating tumor penetration and durable responses. Ficerafusp alfa is being developed for head and neck squamous cell carcinoma, as well as other solid tumor types.
Source: Bicara Therapeutics
